Adverse Event Reporting Delay Is Most Common Cause Of FDA Postmarketing Citations
This article was originally published in The Pink Sheet Daily
Executive Summary
Failure to develop written procedures and issues of non-reporting are also frequently cited by FDA’s Postmarketing Adverse Drug Experience Reporting Compliance Program.